Page 1

October 20 , 2021 poxel Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2021 • TWYMEEGⓇ ( Imeglimin hydrochloride ) launched in Japan on September 16 for the treatment of type 2 diabetes • Milestone payment for TWYMEEG's approval in Japan of JPY 1.75 billion ( approximately EUR 13.2 million , USD 15.8 million ) 1 paid by Sumitomo Dainippon Pharma to Poxel in July 2021 • Patient enrollment in PXL065 Phase 2 ( DESTINY - 1 ) trial in NASH completed in September with results expected in Q3 2022 • Phase 2a clinical Proof of Concept ( POC ) biomarker studies of PXL065 and PXL770 in X - linked adrenoleukodystrophy ( ALD ) planned to initiate in early 2022 with data expected by year end 2022 • As of September 30 , 2021 , cash and cash equivalents were EUR 37.2 million ( USD 43.2 million ) LYON , France -- ( BUSINESS WIRE ) -- POXEL SA ( Euronext – POXEL - FR0012432516 ) , a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology , including non - alcoholic steatohepatitis ( NASH ) and rare disorders , today provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30 , 2021 . " During the third quarter , we continued to make significant progress and accomplished a number of important clinical and corporate objectives . The TWYMEEGⓇ approval last June and subsequent launch on September 16 have increased our financial position and will continue to bolster our financial foundation with associated future royalties and sales - based payments . We are extremely proud to have brought TWYMEEGⓇ to patients in Japan through our fruitful partnership with Sumitomo Dainippon Pharma . In line with our commitment towards NASH , in September , we completed patient enrollment in the PXL065 Phase 2 trial where we anticipate reporting topline results in Q3 2022 , " said Thomas Kuhn , CEO of Poxel . " For the remainder of this year , we are fully committed to advancing our programs , particularly to support the important clinical milestones of initiating the Phase 2a clinical Proof of Concept biomarker studies of PXL065 and PXL770 in ALD in early 2022 and completing the PXL065 Phase 2 trial in NASH in Q3 2022. Our recent accomplishments highlight our capability to deliver on our goals which are aligned with Poxel's mission to develop innovative therapeutics for patients living with metabolic diseases , ” Mr. Kuhn added .